- Home
- RIGL vs HLLY Comparison
RIGL vs HLLY Comparison
Compare RIGL & HLLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | HLLY |
|---|---|---|
| Founded | 1996 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 493.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | HLLY |
|---|---|---|
| Price | $37.67 | $4.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $43.20 | $4.43 |
| AVG Volume (30 Days) | 585.3K | ★ 780.3K |
| Earning Date | 03-03-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | $282,076,000.00 | ★ $598,132,000.00 |
| Revenue This Year | $65.53 | $1.75 |
| Revenue Next Year | $0.22 | $5.07 |
| P/E Ratio | $6.05 | ★ N/A |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $15.50 | $1.60 |
| 52 Week High | $52.24 | $4.43 |
Technical Indicators
Market Signals| Indicator | RIGL | HLLY |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 51.67 |
| Support Level | $37.00 | $4.09 |
| Resistance Level | $39.49 | $4.28 |
| Average True Range (ATR) | 2.62 | 0.17 |
| MACD | -0.73 | -0.01 |
| Stochastic Oscillator | 4.46 | 55.10 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About HLLY Holley Inc.
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.